All In Biotech

Drug Trial Radar · NCT07487376

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults

A Phase I, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBIO-600 in Overweight or Obese Adult Participants (IBIO-600-CT001).

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

May 24, 2026

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
iBio, Inc.Industry
Sponsor type
Industry
First posted
Mar 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn which dose of study drug IBIO-600 has the right balance of safety, tolerability and impact on body composition in overweight and obese adult participants.

Conditions

  • Overweight , Obesity

Interventions

  • IBIO-600Drug

    IBIO-600 Subcutaneous injection

  • PlaceboDrug

    Matching placebo; subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of the safety and tolerability of a single dose of IBIO-600Time frame: From Day 1 through Day 252 (end of study).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Veritus Research

    Bayswater, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.